Stockreport

A First Look At Lyell Immunopharma [Seeking Alpha]

Lyell Immunopharma, Inc.  (LYEL) 
PDF Ronde-cel's registrational trial targets impressive potential results, with pivotal data expected mid-2027 and BLA submission in 2H27. LYL273, recently in-licensed fo [Read more]